Targets › CD36
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Sep 2027.
Multifunctional glycoprotein that acts as a receptor for a broad range of ligands. Ligands can be of proteinaceous nature like thrombospondin, fibronectin, collagen or amyloid-beta as well as of lipidic nature such as oxidized low-density lipoprotein (oxLDL), anionic phospholipids, long- and very long-chain fatty acids and bacterial diacylated lipopeptides. (UniProt, P16671)
Open in Phaseline: the race on CD36, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Pilatus Biosciences | PLT012 anti-CD36 monoclonal antibody | CD36 | Phase 1 | Advanced Malignant Solid Tumor | Sep 2027 |
Advanced Malignant Solid Tumor (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.